PROCEPT BioRobotics (PRCT) announced that three prostate cancer procedures in the WATER IV Prostate Cancer, PCa, trial were successfully completed in an Ambulatory Surgery Center, ASC, using Aquablation therapy by Dr. Rahul Mehan of East Valley Urology in Scottsdale, Arizona. WATER IV PCa is a U.S. FDA investigational device exemption approved clinical study comparing Aquablation therapy and radical prostatectomy for the treatment of localized prostate cancer. The study will evaluate and compare the safety and efficacy of Aquablation therapy and radical prostatectomy for men with Grade Group 1 to 3 localized prostate cancer.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRCT:
- Leerink sees positive readthrough for Procept after CMS’ OPPS proposed rule
- 3 Best Stocks to Buy Now, 7/16/2025, According to Top Analysts
- Procept BioRobotics price target lowered to $68 from $71 at Morgan Stanley
- Positive Outlook on PROCEPT BioRobotics Amid New Fee Schedule Developments for Aquablation
- Buy Recommendation for Procept BioRobotics Supported by Favorable CMS Updates and Reimbursement Stability